Cepheid Gets CE Mark for Drug-Resistant Bacteria Dx; Partners with Pharma for US Development | GenomeWeb

This article has been updated from a previous version to include information about Cepheid's pharmaceutical partnerships around the Xpert Carba-R assay.

NEW YORK (GenomeWeb) — Cepheid this week announced the European release of a new on-demand molecular diagnostic designed to test for multi-drug resistant pathogens, and said that it is collaborating with three US pharmaceutical partners to further develop the assay to help physicians prescribe the most beneficial antibiotics for patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.